{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:28:50Z","timestamp":1777858130800,"version":"3.51.4"},"reference-count":33,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2013,10,9]],"date-time":"2013-10-09T00:00:00Z","timestamp":1381276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:p>\n                    The pharmacological properties of two NK1 antagonists were studied in comparison with a benzodiazepine during a 7% CO\n                    <jats:sub>2<\/jats:sub>\n                    challenge in a population of healthy volunteers selected for a high sensitivity to the challenge. In total, 19 healthy subjects, pre-screened for their responsiveness to the 7% CO\n                    <jats:sub>2<\/jats:sub>\n                    test, took part in the randomised, double-blind, cross-over, incomplete block design study. After receiving treatment or placebo, the volunteers were subjected to three 7% CO\n                    <jats:sub>2<\/jats:sub>\n                    challenges each for a time of 20 min. The treatment consisted of the administration of the following three active drugs: a single dose of benzodiazepine alprazolam (0.75 mg) and a single dose of the NK1 antagonists vestipitant (GW597599) (15 mg) and vofopitant (GR205171) (25 mg). Anxiety during the challenge was evaluated with Visual Analogue Scale-Anxiety (VAS-A) and with Panic Symptom List (PSL III-R). Respiratory parameters, heart rate and skin conductance were also recorded. Compared with placebo, vestipitant showed a significant reduction ( p&lt;0.05) in anxiety assessed on the VAS-A scale (\u0394VAS-A%) while alprazolam significantly ( p&lt;0.01) attenuated the PSL III-R total score. Vofopitant did not show any anxiolytic effect. In the comparison analysis between placebo and drugs, none of the respiratory and other physiological parameters showed a statistically significant difference.\n                  <\/jats:p>","DOI":"10.1177\/0269881113507641","type":"journal-article","created":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T15:43:10Z","timestamp":1381419790000},"page":"491-497","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Anxiolytic effects of vestipitant in a sub-group of healthy volunteers known to be sensitive to CO\n                    <sub>2<\/sub>\n                    challenge"],"prefix":"10.1177","volume":"28","author":[{"given":"Stefano Zanone","family":"Poma","sequence":"first","affiliation":[{"name":"Department of Neuroscience, University of Padova, Italy"},{"name":"Discovery Medicine, Neuroscience CEDD, Medicine Research Centre, GSK Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Merlo-Pich","sequence":"additional","affiliation":[{"name":"Neuroscience CEDD, Medicine Research Centre, GSK Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Bettica","sequence":"additional","affiliation":[{"name":"Discovery Medicine, Neuroscience CEDD, Medicine Research Centre, GSK Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Bani","sequence":"additional","affiliation":[{"name":"Discovery Medicine, Neuroscience CEDD, Medicine Research Centre, GSK Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Fina","sequence":"additional","affiliation":[{"name":"Neuroscience Discovery Biometrics, GSK Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Ziviani","sequence":"additional","affiliation":[{"name":"Discovery Medicine, Neuroscience CEDD, Medicine Research Centre, GSK Verona, Italy"},{"name":"Centro Ricerche Cliniche (Clinical Research Centre) of Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Milleri","sequence":"additional","affiliation":[{"name":"Discovery Medicine, Neuroscience CEDD, Medicine Research Centre, GSK Verona, Italy"},{"name":"Centro Ricerche Cliniche (Clinical Research Centre) of Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,10,9]]},"reference":[{"key":"bibr1-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4530(01)00075-0"},{"key":"bibr2-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1002\/da.20048"},{"key":"bibr3-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1177\/0269881106063889"},{"key":"bibr4-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1177\/0269881111400650"},{"key":"bibr5-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1177\/0269881111408455"},{"key":"bibr6-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(94)00045-S"},{"key":"bibr7-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2013.04.008"},{"key":"bibr8-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.1.79"},{"key":"bibr9-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.06.013"},{"key":"bibr10-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.52.6.1090"},{"key":"bibr11-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2005.12.045"},{"key":"bibr12-0269881113507641","doi-asserted-by":"publisher","DOI":"10.2174\/138161209788168074"},{"key":"bibr13-0269881113507641","volume-title":"Note for guidance on clinical investigations of medicinal products indicated for the treatment of Panic Disorders","author":"EMEA European Medicines Agency","year":"2003"},{"key":"bibr14-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7967(99)00074-1"},{"key":"bibr15-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.03.029"},{"key":"bibr16-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00160-1"},{"key":"bibr17-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.04.022"},{"key":"bibr18-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0b013e32832ec594"},{"key":"bibr19-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.07.013"},{"key":"bibr20-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1993.01820160076009"},{"key":"bibr21-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1126\/science.281.5383.1640"},{"key":"bibr22-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2006.11.014"},{"key":"bibr23-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2010.11.012"},{"key":"bibr24-0269881113507641","doi-asserted-by":"publisher","DOI":"10.2174\/1381612053764779"},{"key":"bibr25-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108097716"},{"key":"bibr26-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200206000-00011"},{"key":"bibr27-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31823608ca"},{"key":"bibr28-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110372543"},{"key":"bibr29-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110364270"},{"key":"bibr30-0269881113507641","volume-title":"Mini International Neuropsychiatric Interview (M.I.N.I.)","author":"Sheehan DV","year":"1994"},{"key":"bibr31-0269881113507641","volume-title":"Manual for the State-Trait Anxiety Inventory, revised edition","author":"Spielberger CD","year":"1983"},{"key":"bibr32-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(89)90255-5"},{"key":"bibr33-0269881113507641","doi-asserted-by":"publisher","DOI":"10.1177\/0269881105056533"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881113507641","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0269881113507641","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881113507641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:08:06Z","timestamp":1777507686000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881113507641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,9]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1177\/0269881113507641"],"URL":"https:\/\/doi.org\/10.1177\/0269881113507641","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,9]]}}}